RxDoctor Payments Data

Vijay Kalaria, MD

Interventional Cardiology · Fort Worth, TXNPI 1205811031

Payments from drug & device makers

$13,413in general payments, 2019–2025

Across 162 payments — averaging $82.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$10K
  • Abbott$642
  • Medtronic$542
  • Heartflow, Inc.$461
  • Novartis$227
  • Johnson & Johnson$217
  • plus $2K from 22 others

What the payments were for

  • Speaking & faculty fees$9,00067%
  • Travel & lodging$620%
  • Food & beverage$4,23532%
  • Education$1171%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,413 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$576,674
Medicare patients
531
Services billed
4,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$205,965
FarxigaDapagliflozin Propanediol69$78,657
XareltoRivaroxaban72$76,715
BrilintaTicagrelor52$46,180
EntrestoSacubitril/Valsartan22$35,450
Repatha SureclickEvolocumab27$25,463
JardianceEmpagliflozin23$24,009
KerendiaFinerenone11$7,520
Metoprolol Succinate627$7,451
ClopidogrelClopidogrel Bisulfate480$5,770
Isosorbide Mononitrate ErIsosorbide Mononitrate355$4,177
Atorvastatin Calcium278$3,141
Prasugrel Hcl45$3,125
Ezetimibe104$2,561
Rosuvastatin Calcium170$2,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$195$205,965199 claims
AstraZenecaFarxiga, Brilinta$9,797$124,838121 claims
Johnson & JohnsonXarelto$217$76,71572 claims
NovartisEntresto$227$35,45022 claims
Boehringer IngelheimJardiance$71$24,00923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →